Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sensorion
  6. Summary
    ALSEN   FR0012596468

SENSORION

(ALSEN)
  Report
Real-time Euronext Paris  -  11:28 2022-10-03 am EDT
0.3550 EUR   -3.27%
09/22Sensorion SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
09/22SENSORION : 1st-half-year results
CO
09/14Sensorion Enrolls First Patient in SENS-401 Clinical Trial
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/27/2022 09/28/2022 09/29/2022 09/30/2022 10/03/2022 Date
0.4005(c) 0.389(c) 0.362(c) 0.367(c) 0.355(c) Last
25 384 20 238 30 320 17 972 59 741 Volume
+0.13% -2.87% -6.94% +1.38% -3.27% Change
More quotes
Estimated financial data (e)
Sales 2022 4,80 M 4,72 M 4,72 M
Net income 2022 -21,2 M -20,9 M -20,9 M
Net Debt 2022 20,1 M 19,7 M 19,7 M
P/E ratio 2022 -1,27x
Yield 2022 -
Sales 2023 5,22 M 5,13 M 5,13 M
Net income 2023 -26,1 M -25,6 M -25,6 M
Net Debt 2023 33,7 M 33,1 M 33,1 M
P/E ratio 2023 -1,04x
Yield 2023 -
Capitalization 28,4 M 27,9 M 27,9 M
EV / Sales 2022 10,1x
EV / Sales 2023 11,9x
Nbr of Employees 38
Free-Float 50,7%
More Financials
Company
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its... 
Sector
Biotechnology & Medical Research
Calendar
10/03 | 08:00amPresentation
More about the company
Ratings of Sensorion
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SENSORION
09/22Sensorion SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
09/22SENSORION : 1st-half-year results
CO
09/14Sensorion Enrolls First Patient in SENS-401 Clinical Trial
MT
09/14Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-4..
CI
09/12Sensorion Receives Positive Opinion in Europe on Orphan Drug Designation for Hearing Lo..
MT
07/01Sensorion Granted Australian Approval for Phase 2a Trial of SENS-401 in Patients Schedu..
MT
07/01Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial o..
CI
06/07Sensorion Wins French Regulatory Nod to Conduct Mid-stage Study of Hearing Preservation..
MT
06/07Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of S..
CI
05/31SENSORION : Proxy Statments
CO
04/28SENSORION : Financial report
CO
04/28Sensorion SA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/15Sensorion : Inside Information / Other news releases
PU
04/14SENSORION : Proxy Statments
CO
03/17Sensorion SA Provides Update on SENS-401
CI
More news
News in other languages on SENSORION
09/22Sensorion : Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise..
09/22Bolsa de Madrid: ¿Powell on? ¡ Powell off!
09/22Powell on ? Powell off !
09/22EN DIRECT DES MARCHES : Veolia, Saint-Gobain, Nexans, Crédit Suiss..
09/22Sensorion SA annonce ses résultats pour le semestre clos le 30 juin 2022
More news
Chart SENSORION
Duration : Period :
Sensorion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SENSORION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,36 €
Average target price 2,80 €
Spread / Average Target 689%
EPS Revisions
Managers and Directors
Nawal Ouzren Chief Executive Officer & Director
Scott D. Myers Chairman
Géraldine Honnet Chief Medical Officer
Otmane Boussif Chief Technology & Scientific Officer
Eric Forquenot de la Fortelle Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SENSORION-80.95%29
MODERNA, INC.-53.44%46 259
LONZA GROUP AG-36.15%36 760
IQVIA HOLDINGS INC.-35.80%33 784
SEAGEN INC.-11.49%25 236
ALNYLAM PHARMACEUTICALS, INC.18.03%24 025